Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer

HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosgrove, Nicola, Eustace, Alex J., O’Donovan, Peter, Madden, Stephen F., Moran, Bruce, Crown, John, Moulton, Brian, Morris, Patrick G., Grogan, Liam, Breathnach, Oscar, Power, Colm, Allen, Michael, Walshe, Janice M., Hill, Arnold D., Blümel, Anna, O’Connor, Darren, Das, Sudipto, Milewska, Małgorzata, Fay, Joanna, Kay, Elaine, Toomey, Sinead, Hennessy, Bryan T., Furney, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533568/
https://www.ncbi.nlm.nih.gov/pubmed/37758711
http://dx.doi.org/10.1038/s41523-023-00572-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533568/
https://www.ncbi.nlm.nih.gov/pubmed/37758711
http://dx.doi.org/10.1038/s41523-023-00572-9

Ejemplares similares